iBio Presents Updates on IBIO-CFB03 Fibrosis Drug Candidate At 2014 Annual Shareholders Meeting

iBio Presents Updates on IBIO-CFB03 Fibrosis Drug Candidate At 2014 Annual Shareholders Meeting

Biotechnology company iBio Inc. recently provided updates at its Annual Meeting for shareholders and attendees on the development progress of IBIO-CFB03 and its potential to address unmet medical needs for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The creator of IBIO-CFB03, Dr. Feghali-Bostwick from the Medical University…

Surfactant SP-D Could Be a Good Blood Biomarker for Pulmonary Fibrosis

Scientists from Japan have found that blood levels of the surfactant protein SP-D could be a good biomarker for idiopathic pulmonary fibrosis, since it leaks into the blood more easily than another similar surfactant protein, called SP-A. The study appeared in the journal BioMedCentral Pulmonary Medicine on December…

Atorvastatin Reduces Pulmonary Fibrosis Symptoms in Rats

Scientists in Iran have found that the lipid-lowering agent atorvastatin may reduce pulmonary injury and fibrosis caused by paraquat–a poison that is toxic to the nervous system. The article was published in the December issue of Advanced Pharmaceutical Bulletin. Pulmonary fibrosis is characterized by thick, scarred lung tissue,…

Pulmonary Fibrosis May Be Caused By Excess Fat in the Lungs

Special cells may dump fat into the lungs of people with pulmonary fibrosis, filling airspaces. Scientists at Thomas Jefferson University in Philadelphia found that decreasing the accumulation of lung fat could help reduce problems associated with this disease. Pulmonary fibrosis is characterized by scarred, thick tissue within the lungs.

Pulmonary Fibrosis Foundation Announces November Fundraisers

The Pulmonary Fibrosis Foundation has just published November’s schedule of ongoing fundraising events. With 10 different programs for getting involved to choose from this month, it should be easy to find something right up your alley, and help support research and development efforts for pulmonary fibrosis, as…

Pacific Therapeutics Announces Pulmonary Fibrosis Diagnosis Breakthrough

As the drug development community continues to invest into pulmonary fibrosis research, new insights are improving both diagnostic and prognostic tools for improving treatment of the disease. Recently, Pacific Therapeutics Ltd. scientists reported in a study entitled “Familial and sporadic idiopathic pulmonary fibrosis:making the diagnosis from peripheral blood”…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums